Drug Trial Radar · NCT01305408
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Last checked: Nov 20, 2026Latest source record: May 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
399
Actual
Start
Mar 2011
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- CephalonIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.
Conditions
- Depression
Interventions
ArmodafinilDrug
Armodafinil tablets, taken orally, once daily in the morning
PlaceboDrug
Matching placebo tablets, taken orally, once daily in the morning
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)Time frame: Day 0 (baseline), Week 8
Locations
130 sites in 14 countries. Site status is shown where the registry gives one.
Teva Investigational Site 225
Birmingham, Alabama
Teva Investigational Site 295
Sherman Oaks, California
Teva Investigational Site 122
Temecula, California
Teva Investigational Site 606
Jacksonville Beach, Florida
Teva Investigational Site 127
Lauderhill, Florida
Teva Investigational Site 608
Tampa, Florida
Teva Investigational Site 116
Atlanta, Georgia
Teva Investigational Site 205
Atlanta, Georgia
Teva Investigational Site 195
Park Ridge, Illinois
Teva Investigational Site 611
Indianapolis, Indiana
Teva Investigational Site 600
Lafayette, Indiana
Teva Investigational Site 603
Watertown, Massachusetts
Teva Investigational Site 207
Brooklyn, New York
Teva Investigational Site 202
New York, New York
Teva Investigational Site 110
Staten Island, New York
Teva Investigational Site 411
Staten Island, New York
Teva Investigational Site 614
Wilmington, North Carolina
Teva Investigational Site 610
Cincinnati, Ohio
Teva Investigational Site 615
Toledo, Ohio
Teva Investigational Site 401
Oklahoma City, Oklahoma
Teva Investigational Site 609
Oklahoma City, Oklahoma
Teva Investigational Site 616
Oklahoma City, Oklahoma
Teva Investigational Site 406
Allentown, Pennsylvania
Teva Investigational Site 403
DeSoto, Texas
Teva Investigational Site 612
Friendswood, Texas
Teva Investigational Site 408
Salt Lake City, Utah
Teva Investigational Site 613
Kirkland, Washington
Teva Investigational Site 605
Spokane, Washington
Teva Investigational Site 134
Buenos Aires, Argentina
Teva Investigational Site 136
Buenos Aires, Argentina
Teva Investigational Site 881
Buenos Aires, Argentina
Teva Investigational Site 884
Buenos Aires, Argentina
Teva Investigational Site 888
Buenos Aires, Argentina
Teva Investigational Site 236
Córdoba, Argentina
Teva Investigational Site 135
Córdoba Capital, Argentina
Teva Investigational Site 371
La Plata, Argentina
Teva Investigational Site 886
La Plata, Argentina
Teva Investigational Site 138
La Plata, Buenos Aires, Argentina
Teva Investigational Site 882
Mendoza, Argentina
Teva Investigational Site 883
Mendoza, Argentina
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.